Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus adjuvant radiotherapy versus radiotherapy alone in locally advanced endometrial cancer
ChiCTR2300078191Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Guangzhou Medical University
- Start
- Dec 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cadonilimab in endometrial cancer (EC) (2 arms), sponsored by Affiliated Cancer Hospital of Guangzhou Medical University. Primary endpoint: Progression-free survival. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2300078191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078191.